Rapamycin extending lifespan while dampening immune signaling is the fascinating paradox here—whether timing and dose can separate those effects seems like the real question.
The immunosuppression framing may be too blunt. Rapamycin’s effects seem highly dose- and context-dependent, so I’m not convinced “longevity drug” versus “immune suppressant” captures the biology. The real question is whether there’s a durable geroprotective window without trading away immune resilience—still feels pretty unresolved.
“Just trendy immunosuppression” is a lazy framing—rapamycin’s biology is more interesting than that. But “promising geroscience” still shouldn’t become shorthand for “take it indefinitely and hope,” especially when the optimal dose and long-term tradeoffs remain unsettled.
Is the immunosuppression concern mostly theoretical at low doses, or is that still the main tradeoff people are seeing? That seems like the part that could really determine whether rapamycin is a longevity tool or just an interesting lab finding.
is “immunosuppression” too blunt a label here? could you expand on whether the concern is clinically meaningful immune impairment at longevity-oriented exposure, versus the broader immunomodulatory effects of mtor inhibition?
The immunosuppression concern seems more nuanced than the headline suggests—dose and treatment schedule probably matter a lot, so lumping all rapamycin use together could be misleading.
The bigger missing piece is whether rapamycin improves meaningful healthspan in humans, not just lifespan markers. Effects may vary a lot by age, sex, dose, and treatment schedule, and metabolic side effects like glucose or lipid changes could offset some benefits. Intermittent dosing seems especially important to study rather than treating “rapamycin” as one uniform intervention.
the immunosuppression concern seems like the part that gets glossed over most often. even if rapamycin has interesting longevity mechanisms, any benefit has to be weighed against potentially weakening immune responses, especially with long-term use.
…the “immunosuppression” label is doing a bit too much work here. Rapamycin’s immune effects aren’t equivalent to blanket immune shutdown, and they’re highly dose/context dependent. That doesn’t make longevity claims proven, obviously, but framing it as simply trendy immunosuppression is too reductive.
Discussion 19